• Home
  • Sector News
    • Technology
    • Energy
    • Financial Services
  • Opinion and Analysis
    • Market Overview
      • Opinion
      • Technical Analysis
      • Fundamental Analysis
      • Investment Idea
    • Stock Market
      • Opinion
      • Technical Analysis
      • Fundamental Analysis
      • Stock Pick
  • Virtus Report

Subscribe to stay informed!

Discover hidden stock market gems and stay up to date with our weekly email newsletter and individual stock ideas

What's Hot

When will the stock-market pain end? Here are 3 clues investors should watch for.

September 26, 2023

Cantor Fitzgerald Maintains Soleno Therapeutics (SLNO) Overweight Recommendation

September 26, 2023

What’s In Store For CarMax In Q2 – Analyst Sees Easing Growth Comparisons, Cost Controls & More – CarMax (NYSE:KMX)

September 26, 2023
Telegram RSS
  • Government
  • Press Releases
  • Stock Market
  • Top Stories
  • Trading Insights
  • Trending
  • About Us
Telegram RSS
Virtus Junxit EquitiesVirtus Junxit Equities
  • Home
  • Sector News
    1. Technology
    2. Energy
    3. Financial Services
    4. View All

    American Society for Clinical Pathology Awarded $631,983 Grant from the CDC to Strengthen the Laboratory Workforce

    September 26, 2023

    OpenAI Discusses Share Sale: Potential $90B Valuation Signals AI Industry Growth – Microsoft (NASDAQ:MSFT)

    September 26, 2023

    Ideal World TV Channel Makes a Grand Return with an Unbeatable Selection of Lifestyle Products

    September 26, 2023

    Mount Sinai Announces New System Chief of Genomic Medicine

    September 26, 2023

    Nat-Gas Prices Decline Due to Warm U.S. Autumn Temperatures

    September 26, 2023

    Brent Crude – Oil Pares Gains in Risk-Averse Trade

    September 26, 2023

    Upwing Energy to Exhibit at SPE Gulf Coast Section Electric Submersible Pumps Symposium, Display Subsurface Compressor System™

    September 26, 2023

    Crude Prices Rise Due to Expectations of Limited Global Oil Supplies

    September 26, 2023

    Aeroflow Healthcare Celebrates Success with Ohio’s Inclusion of Diaper Tax Exemption in HB 33

    September 26, 2023

    Stocks Plunge as Confidence in the U.S. Economic Outlook Declines

    September 26, 2023

    17 Greenberg Traurig Attorneys Named 2023 LMG Life Sciences Guide ‘Life Science Stars’

    September 26, 2023

    Costco (NASDAQ:COST) Exceeds Q4 Expectations

    September 26, 2023

    When will the stock-market pain end? Here are 3 clues investors should watch for.

    September 26, 2023

    Cantor Fitzgerald Maintains Soleno Therapeutics (SLNO) Overweight Recommendation

    September 26, 2023

    What’s In Store For CarMax In Q2 – Analyst Sees Easing Growth Comparisons, Cost Controls & More – CarMax (NYSE:KMX)

    September 26, 2023

    Oppenheimer Maintains U.S. Bancorp. (USB) Outperform Recommendation

    September 26, 2023
  • Opinion and Analysis
    • Market Overview
      • Opinion
      • Technical Analysis
      • Fundamental Analysis
      • Investment Idea
    • Stock Market
      • Opinion
      • Technical Analysis
      • Fundamental Analysis
      • Stock Pick
  • Virtus Report
Get Access
Virtus Junxit EquitiesVirtus Junxit Equities
Home»Trending»Is Chewy a Buy Now?
Trending

Is Chewy a Buy Now?

James TaylorBy James TaylorSeptember 16, 2023Updated:September 16, 2023No Comments2 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

There are reasons to consider buying Chewy stock despite recent challenges. The pet-ownership rate in the US has declined slightly, which may be attributed to the rising costs of taking care of pets. However, Chewy’s low prices as an online pet supply store and its convenience make it an attractive option for consumers. Additionally, pet owners still have a strong emotional connection with their pets and are willing to spend more on them. Chewy’s ongoing growth and projected profitability also contribute to its potential as an investment. While the stock’s recent performance has been affected by factors such as the COVID-19 pandemic and short-selling, its future prospects are promising. However, it’s worth noting that the stock is currently considered expensive, and there is a potential for continued volatility.

Four reasons Chewy stock is a buy

1. Chewy is often the low-price leader

Chewy offers competitive prices compared to brick-and-mortar retail stores. Its online-only model allows it to avoid expenses related to physical stores and optimize its distribution and fulfillment framework.

2. It’s also convenient

Chewy caters to the growing online shopping trend, with a significant portion of pet supply sales yet to shift online. The convenience of Chewy’s platform positions it well for further growth.

3. Actually, people are still pet-crazy

Despite a slight decline in pet ownership, pet owners continue to show strong attachment and a willingness to invest in their pets. The total spending on pets is expected to increase this year, presenting an opportunity for Chewy.

4. The company’s ongoing growth proves reasons 1 through 3

Chewy’s revenue is projected to grow, leading to expected profitability in the coming years. The potential for future growth makes it an attractive investment.

While there are risks associated with Chewy, such as volatility and the stock’s high valuation, for risk-tolerant investors, it could be an intriguing investment option.

James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Chewy.

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Previous ArticleAre you ready to pay $10 or more for a burger?
Next Article Amazon Searches for Its Next Big Hit
James Taylor
  • Website
  • X (Twitter)

A writer and finance enthusiast who loves diving into the exciting world of stocks, commodities, forex, and crypto. I'm all about making the financial markets less intimidating and more accessible, so I write engaging content that simplifies complex concepts and shares practical investment strategies. Whether you're a seasoned investor or just getting started, I've got your back! But hey, life isn't all about work, right? On weekends, you'll find me hanging out and having a blast with my awesome friends and family. We love bonding over shared interests, trying out new adventures, and simply enjoying each other's company. Striking that balance between work and play is super important to me, because what's the point of success if you can't share it with the people you love? So, if you're up for some financial market insights and a good dose of weekend fun, stick around! Together, we'll navigate the money world and make the most of our time off. Let's learn, grow, and create memories along the way!

Related Posts

Cantor Fitzgerald Maintains Soleno Therapeutics (SLNO) Overweight Recommendation

September 26, 2023By James Taylor0

If You Invested $2,000 in PubMatic in 2020, This Is How Much You Would Have Today

September 26, 2023By James Taylor0

VIS Makes Notable Cross Below Critical Moving Average

September 26, 2023By James Taylor0

Leave A Reply Cancel Reply

Our Picks
Technology

American Society for Clinical Pathology Awarded $631,983 Grant from the CDC to Strengthen the Laboratory Workforce

By James TaylorSeptember 26, 2023
Financial Services

Aeroflow Healthcare Celebrates Success with Ohio’s Inclusion of Diaper Tax Exemption in HB 33

By James TaylorSeptember 26, 2023
Technology

OpenAI Discusses Share Sale: Potential $90B Valuation Signals AI Industry Growth – Microsoft (NASDAQ:MSFT)

By James TaylorSeptember 26, 2023
Financial Services

Stocks Plunge as Confidence in the U.S. Economic Outlook Declines

By James TaylorSeptember 26, 2023
Stay In Touch
  • Facebook
  • Twitter
  • Pinterest
  • Instagram
  • YouTube
  • Vimeo
Don't Miss
Trending

Cantor Fitzgerald Maintains Soleno Therapeutics (SLNO) Overweight Recommendation

By James TaylorSeptember 26, 2023

Cantor Fitzgerald has maintained its coverage of Soleno Therapeutics (NASDAQ: SLNO) with an Overweight recommendation, according to Fintel. Analysts forecast a 183.97% upside for Soleno Therapeutics, with an average one-year price target of 12.58. The price targets range from a low of 8.08 to a high of $19.95. This represents…

What’s In Store For CarMax In Q2 – Analyst Sees Easing Growth Comparisons, Cost Controls & More – CarMax (NYSE:KMX)

September 26, 2023

Oppenheimer Maintains U.S. Bancorp. (USB) Outperform Recommendation

September 26, 2023

If You Invested $2,000 in PubMatic in 2020, This Is How Much You Would Have Today

September 26, 2023
FEATURED INSIGHTS​
Top Stories

When will the stock-market pain end? Here are 3 clues investors should watch for.

By James TaylorSeptember 26, 2023
Trending

Cantor Fitzgerald Maintains Soleno Therapeutics (SLNO) Overweight Recommendation

By James TaylorSeptember 26, 2023
Trading Insights

What’s In Store For CarMax In Q2 – Analyst Sees Easing Growth Comparisons, Cost Controls & More – CarMax (NYSE:KMX)

By James TaylorSeptember 26, 2023

Subscribe to stay informed!

Discover hidden stock market gems and stay up to date with our weekly email newsletter and individual stock ideas

Telegram RSS
  • Home
  • Privacy Policy
  • Disclaimer
  • Virtus Report
  • Get Access
  • About Us
© 2023 Virtus Junxit LLC

Type above and press Enter to search. Press Esc to cancel.